The Business Research Company’s report on the Intermittent Claudication Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the intermittent claudication industry?
The increasing cases of peripheral artery disease (PAD) are expected to fuel the growth of the intermittent claudication market going forward. Peripheral artery disease refers to a circulatory condition where narrowed arteries reduce blood flow to limbs, causing pain, numbness, and complications. Increasing cases of peripheral artery disease are attributed to factors such as an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. Peripheral artery disease (PAD) causes intermittent claudication by reducing blood flow to leg muscles during exercise, leading to pain and cramping due to oxygen deprivation. For instance, in June 2023, according to the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, peripheral artery disease (PAD) affects 7-12 million in the U.S. and 200 million globally. Therefore, the increasing cases of peripheral artery disease (PAD) are driving the growth of the intermittent claudication market.
Access Your Free Sample of the Global Intermittent Claudication Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp
What is the estimated market size of the intermittent claudication sector by 2029, based on current forecasts?
The intermittent claudication market size has grown strongly in recent years. It will grow from $12.81 billion in 2024 to $13.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rise in peripheral artery disease, increase in awareness regarding vascular diseases, growth in geriatric population, increase diagnosis rates, and rise in healthcare expenditure.
The intermittent claudication market size is expected to see strong growth in the next few years. It will grow to $17.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing prevalence of diabetes, rising prevalence of obesity, increasing prevalence of cardiovascular diseases, rising alcohol and tobacco consumption, and increasing healthcare spending. Major trends in the forecast period include advancements in pad diagnostics, integration of wearable devices, personalized medicine integration, shift towards drug-eluting stents, and advancements in stem cell therapy.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp
Who are the top players in the intermittent claudication market?
Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.
What are the major trends in the intermittent claudication market?
Major companies operating in the intermittent claudication market are focusing on advanced medication therapies, such as RIPK1 inhibitors, to enhance treatment outcomes for patients suffering from peripheral artery disease (PAD) with intermittent claudication, aiming to improve blood flow, reduce inflammation, and prevent disease progression. RIPK1 inhibitors refer to targeted drugs that block RIPK1 kinase activity, reducing inflammation and cell death. For instance, in August 2022, GenFleet, a China-based biotechnology company, received US Food and Drug Administration (FDA) approval for a Phase II clinical trial of GFH312, an innovative therapy for peripheral artery disease (PAD) with intermittent claudication (IC). This randomized, double-blinded, placebo-controlled study will be conducted at 15 research centers. GFH312 is a RIPK1 inhibitor that has shown promise in preclinical studies by curbing the inflammatory response in animal models.
Which geography holds the highest intermittent claudication market share?
North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report
How do different segments contribute to the overall expansion of the intermittent claudication market?
The intermittent claudication market covered in this report is segmented –
1) By Type: Medication Therapies, Revascularization
2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline
2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021
How is the intermittent claudication market defined, and what are its core characteristics?
Intermittent claudication is a condition characterized by muscle pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is relieved by rest. It is typically caused by peripheral artery disease (PAD), which results from narrowed or blocked arteries reducing blood flow to the muscles. The pain is often due to insufficient oxygen supply (ischemia) to the affected muscles.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
